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Abstract: The recent development of new oral anticoagulants, of which dabigatran etexilate is 
currently at the most advanced stage of development, is the greatest advance in the provision of 
convenient anticoagulation therapy for many years. A new oral anticoagulation treatment, dabigatran 
etexilate, is already on the market in Europe. The main interest probably will be to improve the 
prescription and the adherence to an effective thromboprophylaxis in medical conditions such as atrial 
fibrillation without bleeding side effects, without the need for monitoring coagulation, and without 
drug and food interactions such as vitamin K anticoagulant (VKA) treatment. Dabigatran is particularly 
interesting for extended thromboprophylaxis after major orthopedic surgery in order to avoid daily 
injection for a month. However, oral long-term treatments such as VKA are not systematically 
associated with a higher compliance level than injected treatments such as low-molecular-weight 
heparins. Indeed, adherence to an oral treatment, instead of the usual daily injection in major orthopedic 
surgery, is complex, and based not only on the frequency of dosing but also on patient motivation, 
understanding, and socio-economic status. New oral anticoagulants may be useful in this way but 
education and detection of risk factors of nonadherence to treatment are still essential.
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Introduction
New oral anticoagulants are being promoted, but some observers have expressed concern 
about adherence to these oral therapies in comparison with low-molecular-weight 
heparin (LMWH) injected by nurses or by patients themselves.
Nonadherence or incomplete adherence to drug prescriptions is common. In long-term 
therapy for chronic disease (such as hypertension and myocardial infarction), it has been 
estimated that only half of all drug doses are taken as prescribed.1,2 Oral anticoagulant 
vitamin K antagonist (VKA) therapy probably has the same problems with adherence, 
although no coagulation monitoring is necessary with dabigatran etexilate (dabigatran). 
However, prescription of dabigatran after orthopedic surgery does not exceed 4 weeks, 
and thus the adherence should be greater than for VKA, which is usually prescribed 
for a period of many years. The problem is the clinical significance of the impact of 
nonadherence. Furthermore, efficacy of any self-administered medication, particularly 
with injection, depends to a large extent on patient compliance.
Compliance with oral treatment
Anticoagulation treatment compliance
Long-term anticoagulation mainly concerns medical issues such as prevention of stroke 
or venous thromboembolism event (VTE) treatment. In these cases VKA is used. Patient Preference and Adherence 2009:3 174
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During these treatments coagulation needs to be monitored 
frequently so that the dose can be adapted to overcome 
the problem of patients receiving chronic VKA therapy 
who have poor anticoagulation control and an increased 
risk of adverse events. Adherence, but also medications and 
food interactions, a small therapeutic window, and many 
other variables lead to the need for frequent anticoagulation 
monitoring with VKA. According to the pharmacokinetic 
profile, the need for monitoring coagulation is higher and 
adaptation is more difficult when half-life of VKA is short. 
Because warfarin has a longer half-life than acenocomarol, 
warfarin is much more often used.3 Despite good compliance 
with VKA (60%), anticoagulation control is often inadequate, 
leading to a risk of bleeding complications.4–6
Daily LWMH injections are more often used after major 
surgery such as orthopedic surgery. Daily self injection of 
LWMH increases the risk of nonadherence, but this risk has 
not been properly evaluated. Furthermore, platelets monitor-
ing is required in France twice a week during the first month 
and once a week thereafter. Adherence to platelets monitoring 
has also not been evaluated.
Compliance with others drugs
As medicines become more effective, access to healthcare 
and patient noncompliance will become the leading causes of 
treatment failure. Haynes et al7 define patient compliance as 
“the extent to which a person’s behaviour, in terms of taking 
medications, following diets, or executing lifestyle changes, 
coincides with medical or health advice.”
Most patient noncompliance factors are common to all 
patients with chronic conditions, including patients treated 
with VKA.
Many factors associated with poor compliance have 
been identified in several studies: frequent dosing, patient 
perception of treatment benefits, poor patient–physician 
communication, lack of motivation, poor socioeconomic 
background, lack of family and social support, young age, 
and predementia patients recently diagnosed as having a 
chronic illness.8 Furthermore, a more specific study about 
warfarin long-term treatment1 has shown that extra-medical 
parameters (such as marital status, living arrangements, 
social problem) interfere with VKA medication (and other 
medications) and lead to noncompliance.
Several studies have found an inverse relationship 
between the number of doses prescribed and compliance. 
Compliance declines as dosage frequency increases.9–11 In a 
study of diabetic patients taking oral hypoglycemic agents, 
compliance rates were 74.8% for once-daily doses and 38% 
for thrice-daily doses.12 On the other hand, the severity of 
disease or the gravity of outcome does not improve treatment 
compliance. In patients with chronic disease, compliance 
rates tend to decrease over time.
Impact of nonadherence
Poor compliance is probably the most common cause 
of failure to respond to medications and poor treatment 
outcomes.13 In a clinical trial, noncompliance has been 
reported to have little impact on treatment efficacy, leading 
to false conclusions about the efficacy of a potentially useful 
drug.14 But poor compliance often leads to additional tests, 
changes in the treatment plan, emergency treatment, or hos-
pitalization,15 which increase the cost of medical care.
Dabigatran etexilate adherence
It is interesting to note that between 1 and 4 hours after 
the surgery, the patient is not always able to swallow any 
medication because of nausea. In this case, we recommend 
starting with an injection of LMWH on the first day to avoid 
any risk of nonefficacy.
For dabigatran, one of the nonadherence risks is a result 
of two capsules needing to be taken together once a day. 
Another risk is the possibility of skipping a dose or taking 
two different doses on the same day. Skipping one dose is 
less important, because the rate of deep vein thrombosis 
(DVT) after discharge decreases, but the risk of a double 
dose is much more dangerous, and only good information at 
the time of prescribing can resolve or decrease this risk. In 
comparison with VKA, dabigatran probably has a lower risk 
because of its wider therapeutic window due to the specificity 
(antithrombin exclusive) of this drug.
After asking patients about preference for oral or subcuta-
neous injection, we have to inform and convince them about 
the risk of skipping or taking a double daily dose of an oral 
anticoagulant. Moreover, physicians should suggest ways 
of improving home adherence such as the use of a pillbox, 
commonly used in confused or elderly patients.
Therefore, with good communication and education, 
especially for patients at risk of nonadherence to a drug 
such dabigatran, dabigatran could be at least as effective 
and safe as VKA.
All authors agree on the benefits of improving rehabilitation, 
by whatever means. Indeed, considering current knowledge 
of surgical physiopathology, the primary issues in the early 
postoperative phase pertain to analgesia, mobilization, acute 
respiratory and cardiovascular issues, delirium, antiemetic 
treatment and nutrition.16 For instance, if pain relief is Patient Preference and Adherence 2009:3 175
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controlled the risk of death is significantly reduced in patients 
given combined general anesthesia and peripheral nerve block 
compared with those who receive only general anesthesia or 
only spinal anesthesia. The beneficial effect of the combined 
use of general peripheral nerve block may be because this 
approach reduces the quantity of general analgesic used to 
control pain and reported pain levels, enabling earlier func-
tional recovery.16–22 It has been demonstrated that improving 
rehabilitation can decrease mortality by 50%.17 Therefore, 
the lack of an injection should also improve rehabilitation 
for many physical and psychological reasons: faster recovery 
of autonomy, and feeling recovered without injection and no 
dependence on a nurse for daily injection.
How to improve adherence
One of the easiest ways to improve adherence is probably 
patient education, although in a recent small, effective, 
randomized study, Laporte et al3 failed to prove a statistical 
relationship between education and compliance. A meta-analy-
sis of educational programs in adult asthmatics confirmed that 
such programs are associated with improved compliance.23
The constant demand on physicians for more rapid patient 
turnover has significantly reduced the time spent with each 
patient. Therefore, the use of nurses and para-medical staff 
to assist patient education and follow-up has been advocated. 
More studies are needed to assess the efficacy of educational 
programs by nurse educators. Special attention should be paid 
to persons receiving three or more drugs, living alone, receiv-
ing drugs from other doctors, and to persons with predementia 
symptoms, as they are at higher risk of nonadherence. Physi-
cians should establish a partnership with the patient and their 
family in these cases. Other ways of improving adherence 
are reducing the number and frequency of pills prescribed, 
developing individualized treatment plans,24 and helping 
patients develop ways of remembering to take each dose. 
Calendar blister packaging seems to improve medication 
compliance, particularly in the elderly and in those with a 
history of noncompliance.25 Telephone-based management 
of oral anticoagulation through a pharmacist-staffed antico-
agulation clinic yielded clinical outcomes that were at least 
as favorable as those associated with traditional office-based 
visits.26 In general, a combination of different strategies 
works better than a single strategy, and long-term interven-
tions may be necessary to increase compliance.
The risk
As noted previously, the risk of forgetting one dose of anti-
coagulant in the postoperative period is not very high after 
discharge because of the decreasing risk of VTE. But the 
risk of forgetting beta-blockers or hypotension medication 
is much higher in elderly patients. Indeed, the risk of myo-
cardial infarction or stroke is obviously higher if treatment 
is skipped. Many countries adopt the practice of stopping 
anticoagulation treatment at discharge or after 7 days, despite 
all recommendations, probably because of painful injection 
related to taking of LMWH, and thus convenience is very 
important. Furthermore, prescribing aspirin to prevent DVT 
after discharge is not unusual, even if the effect is known to 
be inadequate in these indications and all recommendations 
warn against prescribing aspirin for DVT prophylaxis.
If a double dose of hypotension medication is given, 
the risk of severe hypotension can be more dangerous than 
a major bleeding after taking an anticoagulant. Because 
elderly or confused patients often take many medications, 
they usually use a pill box. Dabigatran or any other treatment 
can be inserted into this pill box with other medications. 
The risk of bleeding is related especially to age and renal 
function. Therefore, ACCP guidelines recommend27 reduc-
ing the dose of anticoagulant in this population. But there 
are no recommendations on the percentage dose reduction 
necessary, because studies on lower-dose LMWH have 
been inadequate to demonstrate efficacy. However, the 
European Medicines Agency (EMEA) recommends a low 
dabigatran dose of 150 mg/day in elderly patients, or those 
with significant renal impairment (CLCR 30 to 50 mL/min), 
or amiodarone treatment. Indeed, this lower dose has been 
validated by studies.28,29
Dabigatran
Dabigatran, a novel, oral, reversible direct thrombin 
inhibitor, is being investigated for several thromboembolic 
diseases and was approved by the EMEA in March 2008 
for the prevention of VTE in adult patients undergoing 
elective total hip or knee replacement. The onset and offset 
of its anticoagulant activity are rapid and predictable. 
In the clinical phase III program, dabigatran (started 
between 1 and 4 hours after surgery, once a day) was found 
to be as effective as enoxaparin (40 mg once a day, started 
12 hours prior to surgery for the primary prevention of 
VTE), and with a similar safety profile, in the two phase 
III trials RE-MODEL30 in Total Knee Replacement (TKR) 
and RE-NOVATE31 in Total Hip Replacement which led 
to approval in the European Union. Dabigatran is an oral 
alternative to subcutaneous enoxaparin for the prevention 
of VTE after total knee and hip replacement. At this time, 
pivotal studies for VTE treatment and prevention of stroke Patient Preference and Adherence 2009:3 176
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in patients with atrial fibrillation are completed, but have not 
yet been presented. This new oral anticoagulant has some 
major advantages over traditional anticoagulants, includ-
ing a lack of need for anticoagulant monitoring and a low 
drug–drug interaction potential, and can be used in both the 
acute and chronic settings. A UK National Health Service 
(NHS) report indicates that only about half the patients 
undergoing major orthopedic surgery who are at high risk of 
thromboembolism complications receive effective thrombo-
prophylaxis. Even if aspirin is not recommended27 it is often 
used in many countries, because it can be taken orally. The 
approval of dabigatran has the potential to greatly improve 
this situation, as it has several advantages over current 
treatments: it is an oral drug that can be easily administered 
in hospital and after discharge, and offers the prospect 
of a longer duration of prophylaxis with high adherence. 
A substudy analysis of BISTRO-II data showed that early 
treatment initiation (within 2 to 4 hours post surgery) was 
more efficacious, without increased bleeding, than delayed 
administration (4 hours).32 The recommended time for 
initiating dabigatran treatment, based on its pharmacokinetic 
profile, is within 1 to 4 hours post surgery, with only half 
a dose the day of surgery. Absorption is slow after the first 
postoperative dose (6 hours), probably due to alterations 
in gastric motility after surgery. In view of the increased 
bleeding risk immediately after surgery, this slow and steady 
absorption profile in the early postoperative period might 
represent an advantageous strategy by reducing the risk of 
postsurgical bleeding.33 Peak concentration (Cmax) occurs 
at about 6 hours after the first dose, which means about 7 
to 10 hours after surgery. In the steady-state, absorption is 
more rapid and Cmax occurs about 2 hours after administra-
tion. Importantly, there was no evidence of the rebound 
phenomenon, which describes a hypercoagulable state that 
occurs after discontinuation of anticoagulant treatment. 
In RE-MODEL, the incidence of acute coronary syndrome 
events remained low and similar between groups for the 
duration of the 3-month follow-up period; this observation, 
together with the lack of any significant between-group dif-
ferences in pulmonary embolism or death during follow-up, 
suggest that there is no rebound effect on coagulation after 
completion of treatment.
Because half-life is 17 hours in elderly patients, if the 
patient forgets or skips one day, the danger after discharge is 
low. Indeed, the risk is very high during the first 7 days and 
decreases thereafter, especially in total knee replacement.
Dabigatran can be given once daily without dose adjust-
ments. A linear correlation exists between prothrombin time, 
thrombin time, ecarin clotting time and plasma dabigatran 
concentration, confirming the predictability of the pharmaco-
kinetics and pharmacodynamics of dabigatran. In the elderly 
population (75 years old) and in patients with significant 
renal impairment (CLCR 30 to 50 mL/min) a reduced dose of 
150 mg is recommended by the EMEA, This new approval 
represents an important step for increasing safety in this 
fragile population, with high risk of bleeding.
A dose of 220 mg once a day is approved for other 
patients, including obese patients, regardless of ethnicity.
Conclusion
Once-daily treatment with the new oral, synthetic anticoagulant 
dabigatran, which requires no coagulation monitoring tests, 
shows promise for improving adherence to extended pro-
phylaxis, to replace aspirin in some countries and LMWH 
in other countries. Adherence, after good patient education, 
should be as good as that for VKA or self-injected LWMH. 
Nevertheless, patients and their family must be made aware 
of the risks of treatment, even though the risk of DVT after 
one missed dose in the postoperative period is very low. The 
use of pill boxes is quite appropriate in some populations 
who are taking multiple medications.
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